Research programme: brain tumour therapies - Replicon NeuroTherapeutics Inc.
Latest Information Update: 26 Apr 2007
Price : $50 *
At a glance
- Originator Replicon NeuroTherapeutics
- Class Oncolytic viruses
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Brain cancer